Actividades asistenciales

ANTIBODY DIRECTED ENZYME PRO-DRUG THERAPY (ADEPT) FOR CANCER TREATMENT USING AN ANTIBODY OR FRAGMENT THAT BINDS TO A CD206 RECEPTOR AND 3-CYCLOPENTYL-ALPHA-PHENYLALANINE-METHOTREXATE
02/07/2026 - Disclosed are methods of treating cancer by administering a first agent comprising an antibody or fragment thereof that binds CD206 present on tumor associated macrophages conjugate to a mutant of...
CRYSTALLINE FORMS OF A PARP1 INHIBITOR
02/07/2026 - The present disclosure relates to salts and solid forms of a compound that are inhibitors of PARP and their uses as therapeutic agents for treating diseases, such as cancer.
COMPOUNDS FOR THE TREATMENT OF MITOPHAGY-RELATED DISEASES
02/07/2026 - The present invention relates to novel uses of compounds as enhancers of mitochondrial functions. The invention further relates to use of such mitochondrial function enhancers for the treatment of...
COMPUTER METHOD, SYSTEM, AND GUI FOR REAL-TIME PROXIMITY FEEDBACK IN INTRALUMINAL CATHETER THERAPY
02/07/2026 - [0000] A computer-implemented method provides real-time visual feedback of intraluminal catheter engagement within a luminal organ of a patient. A catheter with electrodes on a distal end...
LUNG MONITORING SYSTEM
02/07/2026 - Broadly speaking, embodiments of the present techniques relate to a lung monitoring system. In particular, the present techniques relate to a method and device for monitoring a patient's lung,...
RECOMBINANT EXPRESSION SYSTEMS AND RADIATION USEFUL FOR THE TREATMENT OF CANCER
25/06/2026 - Recombinant expression systems and radiation useful for the treatment of cancer The invention relates to a recombinant expression system comprising a nucleic acid construct, particularly for use...
S100A1 PROTEIN-DERIVED PEPTIDE FOR USE IN TREATING CANCER OR IN TREATING OR PREVENTING ANTINEOPLASTIC AGENT-MEDIATED CYTOTOXICITY, CANCER THERAPY-RELATED CARDIAC DYSFUNCTION OR CANCER THERAPY RELATED HEART FAILURE
25/06/2026 - The present invention pertains to a peptide of the S100A1 protein for use in the treatment or prevention of antineoplastic agent-mediated cytotoxicity or cancer therapy-related cardiac dysfunction...
INHIBITORY COMPOUNDS
25/06/2026 - The present invention relates to certain compounds that function as inhibitors of DHX9 activity (RNA Helicase A / RHA or Nuclear DNA Helicase II / NDH II). The present invention also relates to...
COMBINATION THERAPIES USING CDK4 INHIBITORS WITH PD-1 AXIS BINDING ANTAGONISTS
25/06/2026 - This invention relates to, in part, a method for treating cancer by administering a CDK4 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an CDK2 inhibitor to a subject...
EGFR INHIBITOR-FUNCTIONALIZED ALBUMIN-BINDING PLATINUM COMPOUNDS FOR CANCER THERAPY
25/06/2026 - The present invention relates to novel EGFR inhibitor-functionalized albumin-binding platinum compounds of formula (I), including in particular EGFR inhibitor-functionalized albumin-binding...
CD70-TARGETED CARS AND ENGINEERED CELLS COMPRISING SAME AND RELATED METHODS
25/06/2026 - [0000] Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically...
KAT6 TARGETING COMPOUNDS
25/06/2026 - The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.
THERAPEUTIC USES OF HER-2 TARGETED BISPECIFIC POLYPEPTIDES
25/06/2026 - Provided are compositions and methods for treating cancers, in particular those characterized with HER2 expression. The compositions include a conditionally-activatable XTENylated...
MULTISPECIFIC MOLECULES BINDING TRAILR2 AND CDH17 AND USES THEREOF
25/06/2026 - The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin 17...
CANCER THERAPY OF SUBJECTS CARRYING MUTATIONS IN A SPLICING FACTOR GENE
25/06/2026 - The present invention is directed to SEL24/MEN1703 for use in the treatment of a patient suffering from cancer and/or for use in increasing the overall survival of a patient suffering from cancer,...
AXL INHIBITORS FOR THE TREATMENT OF MASTOCYTOSIS
25/06/2026 - Mastocytosis is a rare and heterogeneous disorder marked by the abnormal accumulation of mast cells (MCs) in various tissues. Tyrosine kinase inhibitors have shown limited efficacy, suggesting...
FUSED AZINES FOR THE TREATMENT OF CANCER
25/06/2026 - The present invention discloses compounds according to Formula I: [Formula I] I wherein A, B, X1, X2, X3, Y, L1, R1, R2, R3, R4, R5, R6, n, p, and q are as defined herein. The present invention...
COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND ANTI-TROP2 ANTIBODY-DRUG CONJUGATE
25/06/2026 - A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a...
THERAPEUTIC STRATEGY FOR TREATING COPPER-MEDIATED PATHOLOGIES
25/06/2026 - The present invention is directed to a novel therapeutic strategy for treating a disease mediated by copper, by inhibiting the function of cellular prion protein (PrP).
COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED MOLECULES TARGETING NECTIN-4 AND EFFECTOR CELL ANTIGENS
25/06/2026 - Disclosed herein are polypeptides and polypeptide complexes that are capable of binding tumor cell antigens and effector cell antigens. In some embodiments, the polypeptides and polypeptide...
ENT1 INHIBITORS IN COMBINATION WITH CAR-T CELL THERAPY
25/06/2026 - Disclosed herein are combinations, methods, and uses comprising administering an ENT1 inhibitor and a CAR-T cell therapy for the treatment of a disease. In some embodiments, the disease is...